Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Lintlha tse Ncha tsa Ente ea Kankere bakeng sa Lihlahala Tse Tiileng

ngotsoeng ke mohlophisi

Kajeno Nouscom e phatlalalitse lintlha tse ncha tse khothatsang tsa phetolelo tse fumanoeng tekong e tsoelang pele ea Mokhahlelo oa 1 e hlahlobang NOUS-209. Lintlha li hlahisitsoe maobane Sebokeng sa Late Breaking Sebokeng sa Selemo sa 2022 sa American Association for Cancer Research (AACR).

NOUS-209, sehlahisoa se etelletseng pele sa Nouscom, ke ente e tsoang kantle ho sethala e shebileng li-neoantigens tse 209 tse arolelanoang. E ntse e batlisisoa tekong ea kliniki ea Mokhahlelo oa 1, e tsamaisoang hammoho le anti-PD-1 checkpoint inhibitor pembrolizumab, bakeng sa phekolo ea Microsatellite Instable High (MSI-H) ea lihlahala tse tiileng tsa maleng, colorectal le gastro-esophageal junction.

Nakong e fetileng e hlahisitse lintlha tsa nakoana tsa kliniki tsa motsoako (o hlahisitsoeng Kopanong ea Selemo le selemo ea Mokhatlo oa Immunotherapy of Cancer's (SITC) ka Pulungoana 2021) e totobalitse matšoao a ts'episang a ts'ebetso ea bongaka ho bakuli ba 12 ba MSI-H.

Lintlha tse ncha tsa phetolelo tse hlahisitsoeng ho AACR 2022 li ts'ehetsa liphetho tsena hape 'me li bonts'itse NOUS-209 e bolokehile, e immunogenic haholo ka matšoao a ts'episang a ts'ebetso ea bongaka. Liphuputso tsa bohlokoa e bile tse latelang:

• Tšireletso ea ente ea ente e bontšitsoe ka tlhahlobo ea ex-vivo IFN-ɣ ELISpot ho 67% ea bakuli ba boemong ba tekanyo ea 1 (n=3), le 100% (n=7) ea bakuli ba boemong ba 2.

• Ho bakuli ba 3 ba nang le li-PRs tsa nako e telele bao li-biopsies tsa tumor tsa pele / ka morao li neng li le teng, repertoire ea intratumoral TCR e ile ea atolosoa 'me ea fapanyetsana phekolo ea poso ka NOUS-209. Keketseho ea T effector memori post kalafo e ile ea bonoa.

• Ho e mong oa bakuli bana ba bararo, TCR e khethehileng ea neoantigen e entsoeng ke ente e ile ea lateloa ho tloha ka thōko ho phekolo ea tumor biopsy post NOUS-209.

• Liphetho li bontša hore lisele tsa CD8+ T tse khethehileng tsa neoantigen, tse susumelitsoeng ke NOUS-209, li atoloha le ho fapanyetsana ha feela kalafo ka NOUS-209, 'me ka katleho li kene ka har'a tumor microenvironment ho etsa mosebetsi o khahlanong le hlahala.

Marwan G. Fakih, MD, Setsebi sa Oncology ea Kalafo ea Duarte California ea City of Hope, le mofuputsi oa Thuto ba itse: “Le hoja re bone tsoelo-pele ea mekhoa ea phekolo ea MSI-High ea lihlahala tse tiileng lilemong tsa morao tjena, ho ntse ho e-na le tlhokahalo e kholo e sa finyelloang. Ka hona ho khothatsa haholo ho bona lintlha tsena tse ncha tsa phetolelo tsa Mokhahlelo oa 1 tse bontšang kamoo NOUS-209 e kenyang katoloso e matla ea lisele tsa T le mefuta-futa ea TCR ho bakuli ba bontšang likarabo tse tšoarellang tsa kliniki. Ke labalabela haholo tlhahlobo e felletseng ea liphetho tsa Mokhahlelo oa 1 le nts'etsopele e eketsehileng ea bongaka. ”

Dr. Elisa Scarselli, Ofisiri e ka Sehloohong ea Saense le Co-Mothehi oa Nouscom, o itse: "Lintlha, tse fumanoeng ho bakuli ba 12 ba metastatic MSI-H, li totobatsa letšoao le tloaelehileng le hlokometsoeng ka mor'a ente ho bakuli ba nang le karabelo e tšoarellang ea kliniki. Ho saena ho khetholloa ke ho atolosoa ha TCR repertoire le mefuta e fapaneng ea li-lymphocyte tse kenang ka tumor tse hlohlellelitsoeng ke ente ea NOUS-209, hammoho le keketseho e tšoanang ea lisele tsa T tse nang le phello ea mohopolo oa phenotype. Ho feta moo, re ile ra khona ho latela lisele tsa T tse hlahisitsoeng ke ente har'a tse atolositsoeng ka mor'a kalafo ka har'a hlahala ea e mong oa bakuli bana.

"Re lebelletse ho aha holim'a lintlha tsa rona tse tlamang tsa bopaki ba mohopolo ka ho sebelisa lithuto tsa bohlokoa ho tsoa tekong e ntseng e tsoela pele ho ts'ehetsa nts'etsopele ea NOUS-209 joalo ka ente ea pele ea neoantigen e tsoang shelofong e shebileng lihlahala tsa MSI-H."

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...